- Hindi News
- National
- Bharat Biotech Covaxin; Australia recognizes India’s first indigenous Covid 19 vaccine
Sydney5 hours ago
India’s indigenous vaccine Covaxin has got travel approval in Australia. That is, now any Indian who has got the vaccine will be able to go to Australia with a vaccination certificate. He will not have to be quarantined for 14 days.
The Australian government made this decision just 2 days before the WHO meeting on Covaxin. The World Health Organization meeting is scheduled to take place on 3 November. Bharat Biotech Company, which makes covaccine, hopes that in this meeting the WHO will give emergency approval to their vaccine.
Hyderabad-based company Bharat Biotech had applied to the WHO on April 19 for approval of the vaccine. Let us inform that the Prime Minister of India, Narendra Modi has also got 2 doses of Covaxin.
5 countries accepted India’s certificate
On Monday, 5 more countries have recognized India’s vaccine certificate. These countries include Estonia, Kyrgyzstan, Palestine, Mauritius and Mongolia.
China’s vaccine also approved
Australia has approved the Indian covaccine as well as the BBIBP-CorV vaccine of the Chinese company Sinoform. In Australia, now 2-2 vaccines of both India and China have been approved. This includes India’s CoveShield and Covaxin, and China’s Sinovac and Sinoform.
Where is the screw stuck in WHO’s approval?
The WHO had earlier held a meeting on 26 October regarding the approval of Covaxin. In this, more data was sought from Bharat Biotech regarding the vaccine. The World Health Organization had asked the company for technical data related to the risks and benefits of the vaccine.
What happened in the WHO meeting on 26 October?
In the last WHO meeting, no decision could be taken on the approval of Covaxin. However, WHO’s ADG of Medicine and Health Products, Maryangela Simao, said that we have faith in India’s vaccine industry. Bharat Biotech is continuously providing us data. Now a decision on this can be taken in the meeting to be held on November 3.
.